To explore the potential side effects of these targets, we analyzed whether druggable genes influence ischemic stroke and found that TNFSF12, SLC22A4, and SPARC influence the occurrence of certain ischemic stroke subtypes. This evidence concerns the gene SLC22A4 and ischemic stroke.